SynthesisJournal of gastrointestinal cancer2026
Sarcopenia Affects the Clinical Efficacy of Immune Checkpoint Inhibitors in Gastric Cancer Patients: a Systematic Review and Meta-Analysis.
Synthesis in Journal of gastrointestinal cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe impact of sarcopenia on immune checkpoint inhibitor (ICI) efficacy and treatment-related adverse events (AEs) in gastric cancer (GC) remains controversial. This meta-analysis aims to elucidate associations between sarcopenia and clinical outcomes in ICI-treated GC patients.
methodsWe systematically searched PubMed, Embase, Scopus, and Web of Science (from inception to May 2, 2025) for English-language studies that met predefined inclusion criteria. Primary outcomes included progression-free survival (PFS) and overall survival (OS) (hazard ratios [HRs] with 95% confidence intervals [CIs]), as well as disease control rate (DCR) and overall response rate (ORR) (odds ratios [ORs] with 95% CIs). Secondary outcomes encompassed treatment-related AEs (ORs with 95% CIs). Heterogeneity was quantified via I² statistics, and sensitivity analyses were performed.
resultsThirteen studies (n = 1,119 GC patients) were included. The prevalence of sarcopenia was 54% (95% CI: 46–62%, p < 0.0001; heterogeneity statistics: I2 = 87%, p < 0.0001). Compared to non-sarcopenic patients, sarcopenic patients demonstrated worse OS (adjusted HR = 1.77, 95% CI: 0.67–4.64, p = 0.16; heterogeneity statistics: I2 = 64%, p = 0.04), reduced PFS (adjusted HR = 2.16, 95% CI: 0.88–5.30, p = 0.07; heterogeneity statistics: I2 = 44%; p = 0.14), lower DCR (OR = 0.54, 95% CI: 0.13–2.34, p = 0.33; heterogeneity statistics: I2 = 77%; p = 0.0006), and decreased ORR (OR = 0.69, 95% CI: 0.53–0.89, p = 0.01; heterogeneity statistics: I2 = 0%; p = 0.97). No significant association was observed between sarcopenia and treatment-related AEs (OR = 1.35, 95% CI: 0.38–4.85, p = 0.51; heterogeneity statistics: I2 = 30%; p = 0.23).
conclusionSarcopenia is prevalent in > 50% of ICI-treated GC patients and may be linked to diminished treatment response and poorer survival outcomes. The absence of increased AE risk supports routine sarcopenia assessment for prognostic stratification in this population. These findings require validation in non-Asian cohorts to establish generalizability.
Indexed as
Identifiers
41649620What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.